Nottingham Forest is trialling a blood test that uses plasma proteomics to assess players’ injury risk and recovery, with the project involving a Glasgow biotech company, Entourage. The trial is aimed at identifying whether biological markers can help flag injury likelihood and track how players recover.
Outlets largely frame the same development: the Evening Standard, The Independent, and the Belfast Telegraph all focus on the club’s trial and the potential value of the test for sports performance. The emphasis differs slightly by outlet. The Evening Standard and The Independent highlight the company’s view that the approach could become a data-driven “Moneyball for biodata,” while The Herald Scotland foregrounds the partnership between the Glasgow biotech and the football club.
Across coverage, the common thread is that the test is intended to inform team decisions through biological indicators rather than relying only on traditional assessment and past injury history.